SCHEMBL10115752

SCHEMBL10115752

CC(C)(C)S(=O)(=O)NC1CCN(C(=O)Nc2ccc(S(=O)(=O)NC3CCCCC3)cc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.54
ALDH1A1 P00352 3/20 0.52
HPGD P15428 3/20 0.52
KMT2A Q03164 5/20 0.51
MEN1 O00255 3/20 0.51
CYP3A4 P08684 2/20 0.49
CYP2D6 P10635 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
NAMPT P43490 1/20 0.49
CYP1A2 P05177 1/20 0.49
GAA P10253 1/20 0.49
GRM4 Q14833 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
MAPT P10636 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10115770 0.88 POLB (0.52) LMNAKMT2ANAMPTMAPT
SCHEMBL10115755 0.88 LMNA (0.54) LMNAALDH1A1KMT2AMEN1MAPT
SCHEMBL10115781 0.86 KMT2A (0.54) LMNAALDH1A1KMT2AMEN1CYP3A4
SCHEMBL10115786 0.86 KMT2A (0.55) LMNAALDH1A1KMT2AMEN1CYP3A4
SCHEMBL10114661 0.86 NAMPT (0.49) LMNACYP3A4CYP2C9NAMPTSMN1; SMN2
SCHEMBL10115754 0.85 KMT2A (0.60) LMNAALDH1A1KMT2AMEN1NAMPT
SCHEMBL10116105 0.85 KMT2A (0.56) LMNAALDH1A1HPGDKMT2AMEN1
SCHEMBL10115527 0.84 LMNA (0.66) LMNAKMT2AGAAMAPT
SCHEMBL12882021 0.84 LMNA (0.53) LMNAALDH1A1KMT2AMEN1
SCHEMBL10115617 0.84 LMNA (0.53) LMNAALDH1A1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R LMNA 1925/4885ALDH1A1 4558/4885HPGD 3487/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R LMNA 2068/4885ALDH1A1 4599/4885HPGD 3475/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R LMNA 1857/4885ALDH1A1 4517/4885HPGD 3476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.